

BrainCool AB (publ): BrainCool introduces new information policy

The board of BrainCool AB (publ) has established and decided on a new information policy in connection with the listing on the Nasdaq First North Growth Market.

With the new information policy, the company will communicate in English as the first language to the stock market and other stakeholders. Current reports will be designed to better clarify and make visible financial data and product information and thus make it easier for market players to analyze BrainCool and its development.

Communication from the CEO and the IR function will mainly take place in writing and at capital market days. Answering emails from individual shareholders is not possible due to time constraints, but they are referred to the aforementioned activities.

With more active and better ongoing information and communication to the market, the company will continue to refrain from assessing prospects and giving forecasts. However, this does not change the previous assessment that BrainCool's ambition is for BrainCool System/IQool to have a turnover of over SEK 100 M in 2025.

Contacts

For more information

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

About BrainCool AB (publ)

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

Attachments

[BrainCool AB \(publ\): BrainCool introduces new information policy](#)